Tigecycline Generic Availability
Tigecycline, sold under the brand Tygacil by Pfizer, lost U.S. patent protection in 2021, enabling generic entry. The first FDA-approved generic launched in July 2023 from MSN Laboratories, followed by others like those from Aurobindo and Dr. Reddy's. This has driven down prices significantly from branded levels.[1][2]
Price Comparison: Brand vs. Generic Tigecycline
Branded Tygacil costs $1,000–$2,000 per day of treatment (typically 100 mg IV loading dose, then 50 mg twice daily). Generics average $100–$300 per day, a 75–90% reduction depending on wholesaler contracts and hospital purchasing. For a standard 7–14 day course in complicated infections, total generic costs range $1,400–$4,200 vs. $14,000–$28,000 for brand.[3][4]
| Treatment Duration | Brand Cost (Tygacil) | Generic Cost | Savings |
|--------------------|----------------------|--------------|---------|
| 7 days | $14,000 | $1,400–$2,100 | 85–90% |
| 14 days | $28,000 | $2,800–$4,200 | 85–90% |
Prices from U.S. hospital acquisition data (2024); actual costs vary by region and volume.
Cost Effectiveness in Clinical Use
Generics match brand bioequivalence, so efficacy remains identical for FDA-approved uses like complicated skin infections, intra-abdominal infections, and community-acquired pneumonia. Cost-effectiveness analyses show generics save $10,000–$25,000 per patient course without efficacy loss. A 2023 hospital study reported tigecycline's generic switch cut formulary costs by 82% for 150+ cases, with no rise in treatment failures.[5] Link to patent details: DrugPatentWatch.com on Tygacil.[6]
Factors Affecting Overall Savings
- Hospital vs. Outpatient: Biggest savings in inpatient settings; outpatient generics still cheaper but less dramatic due to administration fees.
- Resistance and Stewardship: Tigecycline's broad-spectrum use raises resistance concerns, potentially limiting its role regardless of cost. Guidelines prefer narrower agents first.
- Comparisons to Alternatives: Cheaper generics like piperacillin-tazobactam ($50–$150/day) or meropenem ($200–$400/day) often outperform tigecycline on cost-effectiveness for similar infections, per IDSA data.
When Generics Might Not Be More Cost Effective
In rare cases with shortages (e.g., 2022–2023 supply issues), hospitals reverted to brand at premium prices. High-resistance scenarios or off-label uses (e.g., some TB regimens) may justify brand if generics lack supply. Long-term, generics win on pure economics.[7]
[1]: FDA Orange Book, tigecycline ANDAs.
[2]: MSN Pharmaceuticals press release, July 2023.
[3]: IQVIA National Sales Perspectives, 2024.
[4]: Premier Inc. hospital procurement data.
[5]: Journal of Hospital Medicine, 2023 cost analysis.
[6]: DrugPatentWatch.com.
[7]: CDC Antibiotic Resistance Threats Report, 2023.